# THE EUROPEAN DIRECTORATE FOR THE QUALITY OF MEDICINES & HEALTHCARE (EDQM)





# Ph. Eur. Reference Standards for Physico-Chemical tests of Biologicals

Dr Sylvie Jorajuria Laboratory Department

European Pharmacopoeia training session on Biologicals 4-5 February 2020





# Outline

- Introduction
  - Ph. Eur. RS in the European Pharmacopoeia
  - · Classification of Ph. Eur. RS
  - Ph. Eur. CRS life cycle
- CRS for qualitative use
  - Case studies: purpose, examples, establishment
- CRS for quantitative use
  - · Case studies: purpose, examples, establishment
- Take home messages
- 3 ©2020 EDOM, Council of Europe. All rights reserved.





# Ph. Eur. Reference standards in the Ph. Eur.

### **General notices**

### Ph. Eur RS:


- established under the aegis of and adopted by the European Pharmacopoeia Commission
- alone authoritative in case of arbitration


# **General Chapter 5.12., 7/2018 corrected 10.0** (chapter for information)

- the term "Reference standard" is used as a general term covering reference substances, preparations and spectra
- RS are used to achieve adequate quality control of medicinal products and their components
- terminology, use, establishment, processing, labelling, storage and distribution, re-test programme
- ©2020 EDQM, Council of Europe. All rights reserved.









# Ph. Eur. RS classification

### **Bioassay**

- International Standards (WHO)
  - Primary standards
  - Value assigned in International Units
- BRP: Ph. Eur. Biological Reference Preparations
  - Secondary standards calibrated in International Units

http://www.who.int/biologicals/reference\_preparations/er



https://www.edqm.eu/en/ph-eur-reference-standards-orders-catalogue

### **Physico-chemical tests**

- CRS: Ph. Eur. Chemical Reference Substances
  - Normally established as primary standards

7 ©2020 EDQM, Council of Europe. All rights reserved.





# Ph. Eur. RS classification by intended use

- Qualitative purpose
  - **identification** of the substance subject of a monograph
  - **identification** of impurities
  - system suitability

to verify that a measurement system is operated within the boundaries of its validation scope


- Quantitative use
  - · quantitative determination of the substance subject of the monograph
  - assigned content


### **Golden rules:**


- > the intended purpose of a CRS is described in a Ph. Eur. monograph
- > CRS are not intended to be used as reference (comparator) products in the context of applications for biosimilars











# **Qualitative use**

11 ©2020 EDQM, Council of Europe. All rights reserved.





# CRS for identification – Main substance

### **Purpose**

**Identification** of substance subject of a monograph, e.g. by **NMR**, LC (crossreference to assay section), ...

**Example:** synthetic peptide (<1300 Da)



01/2013:1636

IDENTIFICATION
corrected 9.6

Carry out either tests A and B or tests B and C.

A. Nuclear magnetic resonance spectrometry (2.2.64).

Preparation: 13 mg/ml. solution in 0.2 M deuterated sodium phosphate buffer solution in pl.5 oR containing 20 µg/ml. of deuterated solution trimethylsiplypropionate R.

Comparison: 13 mg/ml. solution of geserelin for NMR identification CRS in 0.2 M deuterated sodium trimethylsiplypropionate R (dissover the contents of a vial of goserelin for NMR identification CRS in 1 this solvent to obtain the desired concentration).

Operating conditions:

Operating conditions:


- field strength: minimum 300 MHz;

Operating conditions:

- field strenglis minimum 300 MHz;

- temperature: 25 °C.

- Results: examine the 'H NMR spectrum from 0 ppm to
9 ppm; the 'H NMR spectrum obtained is qualitatively
similar to the 'H NMR spectrum obtained with goserelin
for NMR Identification CRS.



### Other examples:

- Buserelin for NMR identification CRS, Terlipressin for NMR identification CRS, Octreotide for NMR identification CRS
- Heparin Ca/Na for NMR identification CRS





# CRS for peak identification of the main substance

### **Purpose**

**Identification** of fragments of substance subject of a monograph, e.g. by **peptide** mapping, ...

### **Example:** rDNA protein




IDENTIFICATION B. Peptide mapping (2.2.55).

Reference solution. Prepare at the same time and in the same manner as for the test solution but using *insulin glargine CRS* instead of the substance to be examined. System suitability:

- the chromatogram obtained with the reference solution is qualitatively similar to the chromatogram of insulin glargine digest supplied with <u>insulin glargine CRS</u>;
- in the chromatogram obtained with the reference solution, identify the peaks due to digest fragments II and III:

symmetry factor: maximum 1.5 for the peaks due to fragments II and III;

Results: the profile of the chromatogram obtained with the test solution corresponds to that of the chromatogram obtained with the reference solution.



### Other examples:

- Teriparatide CRS
- Follitropin for peptide mapping and glycan analysis CRS
- Human coagulation factor IX (rDNA) CRS, Etanercept CRS, Infliximab CRS
- 13 ©2020 EDQM, Council of Europe. All rights reserved.






# CRS for identification - Main substance


### **Establishment**

Key quality attribute = identity

- The material selected complies with the relevant requirements of the monograph
- · In addition, the characterisation goes further and the structure is elucidated applying a variety of techniques, including NMR (1H,COSY, TOCSY) and mass spectrometry



COSY/TOCSY - Goserelin for NMR identification CRS



MS TIC (Total Ion Chromatogram) - Insulin glargine CRS





# CRS for identification – Impurity

### **Purpose**

Identification of impurities of the substance subject of a monograph, often in a test for related substances using liquid chromatography method (LC), because of:

specific limit for impurity

System suitability test of chromatographic method:

selectivity: resolution, peak-to-valley ratio

**Example:** synthetic peptide




Related substances. Liquid chromatography (2.2.29). Reference solution (a). Dissolve the contents of a vial of D-His-buserelin CRS (impurity A) in the mobile phase. Dilute an appropriate volume of this solution in the mobile phase to obtain a final concentration of 1 mg/mL. Add 1.0 mL of the test solution to 1.0 mL of this solution.

Identification of impurities: use the chromatogram obtained with reference solution (a) to identify the peak due to

System suitability: reference solution (a):

resolution: minimum 1.5 between the peaks due to impurity A and buserelin.

impurity A: maximum 2.5 per cent;



15 ©2020 EDQM, Council of Europe. All rights reserved.





# CRS for identification – Impurity

### **Establishment**

Key quality attribute = **identity** 

In general, the material is further characterised:

- chromatographic purity using method of intended use
- the intended use is verified
- the structure is elucidated by NMR

**Important**: only the information necessary for the intended use(s) is provided; no additional information e.g. purity, etc. is provided





# CRS Mixtures for synthetic peptides

### **Purpose**

Identification of impurities of the monograph substance, often in a test for related substances using a chromatographic method (LC), because of:

specific limit for impurity

System suitability test of chromatographic method: **selectivity**: resolution, peak-to-valley ratio

- → Composition (see monograph): several impurities with/without main compound
- →"for system suitability CRS", "for peak identification CRS", "impurity mixture CRS"

**Examples:** Buserelin for peak identification CRS

Oxytocin/desmopressin validation mixture CRS

Terlipressin impurity mixture CRS Octreotide impurity mixture CRS

17 ©2020 EDQM, Council of Europe. All rights reserved.





# CRS Mixtures for rDNA proteins

### **Purpose**

To assess the system suitability test of chromatographic method (resolution, peak-to-valley ratio)




- Deamidation, oxidation, aggregation products:
  - · can alter immunogenicity, potency, safety and efficacy of the substance
  - such impurities may be present at low levels in drug substance
- System suitability: need for stressed samples with increased amount of related proteins
- Ready to use CRS for resolution solutions are a more robust option than in situ degradation solutions prepared by users. The latters may be variable and not necessarily reproducible





# CRS Mixtures for rDNA proteins

- 1) Test for oxidised and deamidated forms
  - Teriparatide (2829)
     Resolution solution: incubation of the substance to be examined at 50°C for 9 days
    - -> replaced by *Teriparatide for system suitability CRS*



• Other examples: Somatropin/desamidosomatropin resolution mixture CRS, Interferon gamma-1b for system suitability CRS with increased deamidated and oxidised forms


19 ©2020 EDQM, Council of Europe. All rights reserved.





# CRS Mixtures for rDNA proteins

- 2) Test for aggregates
- Erythropoietin concentrated solution (1316)
   Reference solution: 2% dilution of the test solution for system suitability purposes
   -> has been replaced by Erythropoietin for SEC system suitability CRS with a defined dimer content







# **CRS Mixtures**

### **Establishment**

Key quality attributes:

### **Identity of impurities:**

normally confirmed by spiking with individual impurity samples

### **Fitness for purpose:**

- · established using the method of intended use
- impurities present in sufficient amount for peak detection / identification
- system suitability assessment

## **Homogeneity:**

· important, especially in case of stressed/degraded samples

21 ©2020 EDQM, Council of Europe. All rights reserved






# **CRS Mixtures**

### **Information provided**

Often a chromatogram in the CRS leaflet -> explicitly mentioned in the monograph No additional information e.g. about amount of impurities etc. is provided







# Quantitative use Assay CRS

©2020 EDQM, Council of Europe. All rights reserved.





# Reference standard for biologicals: assignment of content

The procedures for assigning a content to a RS depends on the type of unit of measurement:


- **Bioassay**: International Units refer to WHO International standard. BRP are established by the EDQM via the Biological Standardisation Programme (BSP)
- Physico-chemical assay: the CRS content :
  - is expressed in mg of peptide/protein per vial
  - is usually assigned based on the **"mass balance"** approach




the extent of testing is greater than when a CRS is used for other purposes (Ph. Eur. chapter 5.12.)









# **RS** Processing

Reference standards processing aims at minimising the **risk of decomposition or degradation** 

Whenever possible, the following presentation is selected:

- · material in solid form
- packaged in containers for single use (i.e. glass vials, ampoules)



CRS for synthetic peptides and rDNA proteins are usually presented as freeze dried materials to be reconstituted at the time of use

27 ©2020 EDQM, Council of Europe. All rights reserved





# Assay CRS – establishment

- 1st step: characterisation of the bulk material
  - Verification of compliance with the monograph
  - Confirmation of identity by orthogonal methods (NMR, TOF-MS)
  - Assignment of a content to the bulk material based on a mass balance approach taking into account water content, acetate (or any other ion) and related peptides
  - Confirmation of purity by orthogonal methods (qNMR)
- 2<sup>nd</sup> step: content assignment
  - Determination of homogeneity
  - Determination of mg of peptide or protein/vial by LC assay in the CRS candidate against the bulk material as external standard
  - Assigned value checked by orthogonal techniques (qNMR)







# Assigned content – Where to find the information?

Example: Teriparatide Leaflet

### **Assay section:**

Calculate the percentage content of teriparatide ( $C_{181}H_{291}N_{55}O_{51}S_2$ ) taking into account the assigned content of teriparatide CRS

### INFORMATION LEAFLET Ph. Eur. Reference Standard Teriparatide CRS batch 2

1. Identification

Catalogue code: Y0001916 Unit Quantity: ca 1 mg

2. Scientific Information

### 2.1 Intended use

Reference Standard for laboratory tests as prescribed in the European Pharmacopoeia only. Established for use with the monograph(s): 2829.

### 2.2 Analytical information related to intended use

: Identification by peptide mapping (annex 1) Chromatogram(s)/spectrum

Test for impurities with molecular masses higher than that of

teriparatide (SEC) (annex 2)

The "as is" content is 0.95 mg of C181H291N55O51S2 per vial

29 ©2020 EDQM, Council of Europe. All rights reserved.






# Leaflet - Where to find the information?

### References substances database | Search European Pharmacopoeic Reference Standards | Search European Pharmacopoeic Reference Reference Standards | Search European Pharmacopoeic Reference Reference Standards | Search European Pharmacopoeic Reference Re

Example: Teriparatide







# Monitoring (retest-programme)

# No expiry date is given: see batch validity statement

- All across the RS lifetime, regular testing is performed in order to assure the continuous "fitness for use" of the CRS
- The frequency depends on the intended use and the stability information (12, 24, 36 or 60 months)
- The properties retested are those that might change in the life cycle of a CRS, e.g.:
  - · Related proteins by LC

31 ©2020 EDQM, Council of Europe. All rights reserved.





# Take home messages (1)

### Ph. Eur. CRS

- official, legally binding standards, an essential part of Ph. Eur. monographs
- established and guaranteed for their intended use(s)
  - not necessarily suitable for other purposes



 if a reference standard is to be used for any purpose other than that for which it has been established, its suitability for the new use has to be fully demonstrated by the user





# Take home messages (2)

### Ph. Eur. CRS

- Relevant:
  - to control the performance of the method
  - to assess acceptance criteria (qualitative, quantitative)
  - to allow independent testing
- · Sustainability of supply must be ensured
- Drift between consecutive batches must be avoided
- EDQM provides RS information (leaflet) and assistance (Helpdesk)
- Ph. Eur. policy on reference standard is reflected in general chapter 5.12.

33 ©2020 EDQM, Council of Europe. All rights reserved.





# Thank you for your attention



Stay connected with the EDQM

EDQM Newsletter: https://go.edqm.eu/Newsletter LinkedIn: https://www.linkedin.com/company/edqm/

Twitter: @edqm\_news

Facebook: @EDQMCouncilofEurope

segment Sentrary - Sen

